Regeneron Pharmaceuticals beat Wall Street estimates for third-quarter results on Tuesday, helped by strong demand for its ...

Shares rose after a jump in sales of the blockbuster Dupixent drug and robust pharmaceutical launches delivered higher ...

Discover why Regeneron Pharmaceuticals, Inc.'s Q3 earnings impress, fueled by Dupixent growth and a robust pipeline. Click ...

France's Sanofi reported a third-quarter profit that beat analysts' expectations on Friday, boosted by strong demand for its ...

Dupixent (dupilumab) has been a breakthrough treatment for people with severe eczema, asthma, and other inflammatory ...

Regeneron investors should embrace the fact that Eylea is no longer a growth product and focus on the rest of the commercial ...

An anti-inflammation injectable drug called dupilumab can reduce mucus buildup and improve breathing among asthma patients, a ...

Regeneron Pharmaceuticals beat Wall Street estimates for third-quarter results on Tuesday, helped by strong demand for its ...

Regeneron posts Q3 earnings of $11.83 per share, topping estimates as Dupixent profits lift results despite weaker Eylea ...

Dupixent’s Q3 sales increased by 26.2%, breaking through the €4bn ceiling for the first time in a single quarter.

Over the last 13 months, Sanofi and Regeneron have revved up the momentum for Dupixent, gaining three new indications for the ...

Sanofi SNY reported third-quarter 2025 adjusted earnings of $1.70 per American depositary share, which beat the Zacks ...